Urology Devices: World Market Outlook 2012-2022
The urology device market is one of the largest markets of the medical devices industry. The market is currently comprised of innovative urology devices for the treatment of a wide range of disorders that include urinary incontinence, prostate cancer, benign prostatic hyperplasia (BPH) and kidney stones. It is an attractive and highly profitable market and therefore an intensely competitive one. This is clearly demonstrated by the considerable number of recent mergers and acquisitions within this sector well as the myriad of devices and technologies that are expected to be launched in the coming years.
Urinary incontinence remained the largest segment in 2011, accounting for 36.9% of the global urology devices. Growth in this market is being driven by patient demographics and a favourable reimbursement landscape in key regions of the market. Our outlook for this market remains positive despite recent safety concerns about mesh slings for women in the US market.
The urology devices market will see growth in the period 2012-2022. Key factors driving growth of the market are a global aging population and the continued rise in chronic diseases and conditions such as obesity and diabetes, which continue to be considered significant risk factors in the development of several urological diseases. Patient and physician adoption has also been significant as a result of the increased awareness of urological disease and the decline in social stigma associated with some urological disorders, particularly urinary incontinence and BPH.
Leading companies operating in the urology devices market continue to focus R&D investments on the development of minimally invasive and non-invasive technologies that are cost-effective and with improved safety profiles. Constrained healthcare budgets, across several key regional markets, have significantly increased the demand for these technologies as they are often able to reduce procedure time and hospital stay, reports indicate.
Emerging markets will continue to provide a significant commercial opportunity for companies operating in this industry as they are expected to continue growing with a double-digit CAGR over the next decade. The continued expansion of healthcare coverage and the increasing disposable income are a few of the myriad of factors boosting growth in these markets.
Urology Devices: World Market Outlook 2012-2022 examines this industry through a comprehensive review of information sources. This report provides our sales forecasts, market share analyses, discussions of technological developments and analyses of commercial drivers and restraints, including SWOT analysis. There are over 110 tables and figures included. The result is a comprehensive market, and industry-centred study, with detailed analyses and informed opinion to benefit your work. Visiongain has determined that the value of the global urology devices market in 2012 will reach $4.6bn.
What makes this report unique?
Visiongain consulted widely with industry experts and full transcripts from these exclusive interviews are included in the report. As such, our reports have a unique blend of primary and secondary sources providing informed opinion. The report provides insight into key drivers and restraints behind contract and programme developments, as well as identifying leading companies. The report also provides a unique blend of qualitative analysis combined with extensive quantitative data including global, submarket and national markets forecasts from 2012-2022 - all highlighting key business opportunities.
Why you should buy Urology Devices: World Market Outlook 2012-2022
Gain an understanding of how to tap into the potential of this market by ordering Urology Devices: World Market Outlook 2012-2022
Urinary incontinence remained the largest segment in 2011, accounting for 36.9% of the global urology devices. Growth in this market is being driven by patient demographics and a favourable reimbursement landscape in key regions of the market. Our outlook for this market remains positive despite recent safety concerns about mesh slings for women in the US market.
The urology devices market will see growth in the period 2012-2022. Key factors driving growth of the market are a global aging population and the continued rise in chronic diseases and conditions such as obesity and diabetes, which continue to be considered significant risk factors in the development of several urological diseases. Patient and physician adoption has also been significant as a result of the increased awareness of urological disease and the decline in social stigma associated with some urological disorders, particularly urinary incontinence and BPH.
Leading companies operating in the urology devices market continue to focus R&D investments on the development of minimally invasive and non-invasive technologies that are cost-effective and with improved safety profiles. Constrained healthcare budgets, across several key regional markets, have significantly increased the demand for these technologies as they are often able to reduce procedure time and hospital stay, reports indicate.
Emerging markets will continue to provide a significant commercial opportunity for companies operating in this industry as they are expected to continue growing with a double-digit CAGR over the next decade. The continued expansion of healthcare coverage and the increasing disposable income are a few of the myriad of factors boosting growth in these markets.
Urology Devices: World Market Outlook 2012-2022 examines this industry through a comprehensive review of information sources. This report provides our sales forecasts, market share analyses, discussions of technological developments and analyses of commercial drivers and restraints, including SWOT analysis. There are over 110 tables and figures included. The result is a comprehensive market, and industry-centred study, with detailed analyses and informed opinion to benefit your work. Visiongain has determined that the value of the global urology devices market in 2012 will reach $4.6bn.
What makes this report unique?
Visiongain consulted widely with industry experts and full transcripts from these exclusive interviews are included in the report. As such, our reports have a unique blend of primary and secondary sources providing informed opinion. The report provides insight into key drivers and restraints behind contract and programme developments, as well as identifying leading companies. The report also provides a unique blend of qualitative analysis combined with extensive quantitative data including global, submarket and national markets forecasts from 2012-2022 - all highlighting key business opportunities.
Why you should buy Urology Devices: World Market Outlook 2012-2022
- 136 pages of comprehensive analysis
- 113 tables, charts, and graphs
- Global urology devices market forecasts between 2012-2022
- 4 urology devices submarket forecasts from 2012-2022
- Urinary Incontinence Devices
- Prostate Cancer Devices
- Benign Prostatic Hyperplasia Devices
- Kidney Stone Devices
- 9 leading national urology devices market forecasts between 2012-2022
- US
- China
- Japan
- India
- Germany
- UK
- France
- Italy
- Spain
- A SWOT analysis
- 6 leading companies profiled and several identified -
- Olympus
- Boston Scientific
- C.R. Bard
- Endo Pharmaceuticals
- Coloplast
- Teleflex
Gain an understanding of how to tap into the potential of this market by ordering Urology Devices: World Market Outlook 2012-2022
1. EXECUTIVE SUMMARY
1.1 Sector Highlights
1.2 Aims, Scope and Format of the Report
1.3 Chapter Outline
1.4 Research and Analysis Methods
1.5 Glossary of Terms Related to the Report
2. INTRODUCTION TO UROLOGY DEVICES AND UROLOGY DISEASES
2.1 Overview of Urological Diseases
2.1.1 Benign Prostatic Hyperplasia (BPH)
2.1.1.1 Economic Burden of BPH
2.1.1.2 Diagnosis of BPH
2.1.1.3 Pharmacogical Treatments for BPH
2.1.1.4 Minimally Invasive Therapies for BPH
2.1.1.4.1 Transurethral Microwave Thermotherapy (TUMT)
2.1.1.4.2 Transurethral Needle Ablation (TUNA)
2.1.1.4.3 Photoselective Vaporisation of the Prostate (PVP)
2.1.1.4.4 Holmium Laser Ablation of the Prostate (HoLAP)
2.1.1.5 Transurethral Resection of the Prostate (TURP)
2.2 Kidney Stones
2.2.1 Kidney Stones Diagnosis
2.2.2 Types of Kidney Stones
2.2.3 Treatment Options for Kidney Stone Disease
2.2.3.1 Non-Invasive and Minimally Invasive Treatment Options
2.2.3.1.1 Extracorporeal Shock Wave Lithotripsy (ESWL)
2.2.3.1.2 Ureteroscopic Surgery: Intracorporeal Lithotripsy
2.2.3.1.3 Percutaenous Nephrolithotomy (PCNL)
2.3 Urinary Incontinence (UI)
2.3.1 Types of Urinary Incontinence
2.3.2 Diagnosis and Treatments
2.3.2.1 Surgery & Devices for Urinary Incontinence
2.3.2.1.1 Slings
2.3.2.1.2 Artificial Urinary Sphincter for Men
2.3.2.1.3 Sacral Nerve Stimulation
2.3.2.1.4 Urethral Bulking Agents (Injectables)
2.3.2.1.5 Other Devices
2.4 Prostate Cancer
2.4.1 Diagnosis and Treatments
2.4.1.1 Radical Retropubic Prostatectomy
2.4.1.2 Prostate Brachytherapy
2.4.1.3 External Beam Radiation
2.4.1.4 Cryosurgery for Prostate Cancer
2.4.1.5 High-intensity Focused Ultrasound (HIFU)
2.5 Regulation of Medical Devices
2.5.1 The US Approval and Regulation System
2.5.2 The EU Approval and Regulation System
2.5.2.1 Post Marketing Surveillance in the EU
3. THE GLOBAL UROLOGY DEVICES MARKET, 2011-2022
3.1 The Global Medical Devices Market, 2011
3.2 The Global Urology Devices Market, 2011
3.2.1 Global Urology Devices Market Forecast, 2012-2016
3.2.2 Global Urology Devices Market Forecast, 2016-2022
4. THE URINARY INCONTINENCE DEVICES MARKET, 2011-2022
4.1 The Urinary Incontinence Devices Market, 2011
4.2 Urinary Incontinence Devices Market Forecast, 2012-2022
4.2.1 Intensely Competitive Market
4.2.2 Decline in Social Stigma is Resulting in Earlier Diagnosis
4.2.3 Changes to Reimbursement in the US has Benefited the UI Market in Recent Years
4.2.4 Changes to Regulations in the US May Slow Growth
4.2.5 Leading Providers of Technologically Advanced UI Devices
4.3 Promising UI Treatments in the Pipeline
4.3.1 EMKinetics
4.3.1.1 EMK TranStim Clinical Research Study
4.3.2 Ferti Care: Transcutaneous Mechanical Nerve Stimulation (TMNS) in the Treatment of Incontinence
5. THE BENIGN PROSTATIC HYPERPLASIA DEVICES MARKET, 2011-2022
5.1 The Benign Prostatic Hyperplasia Devices Market, 2011
5.2 Benign Prostatic Hyperplasia Devices Market Forecast, 2012-2022
5.2.1 Increasing Prevalence of BPH will Keep the Market Expanding
5.2.2 Low Patient Compliance to Medications Ensures Strong Demand for Devices
5.2.3 Demographics and Continued Innovation will Offset Economic Issues in the Market
5.3 Promising BPH Devices in the Pipeline
5.3.1 NeoTract Inc.
5.3.1.1 UroLift System Clinical Trials
6. THE PROSTATE CANCER DEVICES MARKET, 2011-2022
6.1 The Prostate Cancer Devices Market, 2011
6.2 The Prostate Cancer Devices Market Forecast, 2012-2022
6.2.1 Increasing Procedure Volume will Continue Expanding the Market
6.2.2 Brachytherapy Market will Grow Significantly in the Coming Years
6.2.3 Robotic Prostatectmoy will Boost Growth Over the Forecast Period
6.3 Promising Prostate Cancer Treatment Devices in the Pipeline
6.3.1 Augmenix Inc.
6.3.1.1 SpaceOAR System Pivotal Study
7. THE KIDNEY STONE DEVICES MARKET, 2011-2012
7.1 The Kidney Stones Devices Market, 2011
7.2 The Kidney Stone Devices Market Forecast, 2012-2022
7.2.1 An Aging Population and Increasing Prevalence of Kidney Stone Disease will Drive the Market in Coming Years
7.2.2 ISWL Technologies will be the Main Drivers of Growth Over the Forecast Period
8. LEADING NATIONAL UROLOGY DEVICES MARKET, 2012-2022
8.1 Regional Breakdown of the Global Urology Devices Market, 2011
8.2 The Global Urology Devices Market: Regional Forecast, 2012-2022
8.3 The US Urology Devices Market
8.3.1 Prostate Cancer Devices will Boost Growth in the US Market
8.3.2 Positive Reimbursement Landscape in the UI market
8.3.3 Safety Concerns Regarding Female Mesh Slings Could Affect the Market
8.3.4 Potential Effects of Upcoming Medical Device Excise Tax
8.4 The European Urology Device Market
8.4.1 Leading Companies in Europe
8.4.2 France and Germany
8.4.3 UK
8.4.4 Spain
8.4.5 Italy
8.5 The Japanese Urology Devices Market
8.6 The Chinese Urology Devices Market
8.6.1 Chinese Aging Population will Increase Demand Over the Next Decade
8.6.2 Increasing Affluence in China will Boost Demand for High-End Technologies
8.7 The Indian Urology Devices Market
9. LEADING COMPANIES IN THE UROLOGY DEVICES MARKET, 2011
9.1 Intensively Competitive Market
9.2 Leading Companies in the Urology Devices Market, 2011
9.3 C.R. Bard
9.3.1 Recent Performance and Analysis, 2011
9.3.2 Recent M&A Activity
9.3.3 Urology Devices
9.3.4 C.R. Bard: Key Urology Devices, 2011
9.4 Coloplast
9.4.1 Recent Performance and Analysis, 2011
9.4.2 Recent M&A Activity, 2011
9.4.3 Urology Devices
9.4.3.1 Coloplast Maintains Competitive Position in the Global Urology Devices Market in 2011
9.4.3.2 Coloplast Remains the Global Leader in the Continence Care Market
9.4.3.3 Urology Patent Disputes
9.4.3.4 Coloplast: Key Urology Devices, 2011
9.5 Endo Pharmaceuticals Holding, Inc.
9.5.1 Recent Performance and Analysis, 2011
9.5.2 Research and Development Efforts, 2011
9.5.3 Recent M&A Activity
9.5.4 Urology Devices
9.5.4.1 Endo Pharmaceuticals: Key Urology Devices, 2011
9.6 Olympus Corporation
9.6.1 Sales and Recent Peformance Analysis, 2011
9.6.2 Recent Acquisitions
9.6.3 Olympus Medical Business: Urology Devices
9.6.3.1 Key Urology Devices, 2011
9.7 Teleflex Inc.
9.7.1 Sales and Recent Performance Analysis, 2011
9.7.2 Teleflex: Urology Devices
9.7.2.1 Changes in Reimbursement in the US Benefit Teleflex Sales
9.7.2.2 Teleflex: Key Urology Devices, 2011
9.7.3 Recent M&A Activity
9.8 Karl Storz
9.8.1Urology Devices
9.9 Companies with Cost-effective Products will Experience Significant Growth
9.10 Other Companies
10. SWOT ANALYSIS OF THE UROLOGY DEVICES MARKET, 2012
10.1 Urology Devices: Industry Trends
10.2 Strengths
10.2.1 A Global Aging Population
10.2.2 Escalating Levels of Worldwide Obesity Amongst the Population
10.2.3 Strong R&D Pipeline Focused on Cost-Effectiveness
10.2.4 Increasing Demand for Minimally Invasive Procedures
10.3 Weaknesses
10.3.1 Poor Economic Conditions in Key Regional Markets
10.3.2 Social Stigma Associated with Urologic Conditions
10.3.3 Safety Concerns in the UI Market
10.4 Opportunities
10.4.1 Increasing Wealth and Expanding Healthcare Coverage in Emerging Markets
10.4.2 Increasing Regulatory Harmonisation Across Major International Markets
10.5 Threats
10.5.1 Comparative Effectiveness Research as an Added Expense
10.5.2 Increasing Bargaining Power of Buyers
10.5.3 Increasing Competition from Pharmacological Options
11. EXPERT OPINION
11.1 Dr. Idan Tamir, CEO, Xenolith Medical
11.1.1 The Urological Device Market
11.1.2 The Impact of Current Regulations in the European and US Medical Devices Market
11.1.3 Current Challenges for Development-Stage Medical Device Companies
11.1.4 XenX: Commercialisation Plan
11.1.5 XenX: Key Adavantages Over Competitors in the Market
11.1.6 The Importance of Expanding into the Emerging Markets
11.1.7 Future projections for the Endourological Device Market
12. CONCLUSIONS
12.1 Overview
12.2 Urinary Incontinence Devices will Remain the Largest Segment
12.3 Prominent Companies in the Market
12.4 The US will Remain the Largest Market for Urology Devices
12.5 Future Outlook and Concluding Remarks
Appendix A
About Visiongain
Appendix B
Visiongain report evaluation form
1.1 Sector Highlights
1.2 Aims, Scope and Format of the Report
1.3 Chapter Outline
1.4 Research and Analysis Methods
1.5 Glossary of Terms Related to the Report
2. INTRODUCTION TO UROLOGY DEVICES AND UROLOGY DISEASES
2.1 Overview of Urological Diseases
2.1.1 Benign Prostatic Hyperplasia (BPH)
2.1.1.1 Economic Burden of BPH
2.1.1.2 Diagnosis of BPH
2.1.1.3 Pharmacogical Treatments for BPH
2.1.1.4 Minimally Invasive Therapies for BPH
2.1.1.4.1 Transurethral Microwave Thermotherapy (TUMT)
2.1.1.4.2 Transurethral Needle Ablation (TUNA)
2.1.1.4.3 Photoselective Vaporisation of the Prostate (PVP)
2.1.1.4.4 Holmium Laser Ablation of the Prostate (HoLAP)
2.1.1.5 Transurethral Resection of the Prostate (TURP)
2.2 Kidney Stones
2.2.1 Kidney Stones Diagnosis
2.2.2 Types of Kidney Stones
2.2.3 Treatment Options for Kidney Stone Disease
2.2.3.1 Non-Invasive and Minimally Invasive Treatment Options
2.2.3.1.1 Extracorporeal Shock Wave Lithotripsy (ESWL)
2.2.3.1.2 Ureteroscopic Surgery: Intracorporeal Lithotripsy
2.2.3.1.3 Percutaenous Nephrolithotomy (PCNL)
2.3 Urinary Incontinence (UI)
2.3.1 Types of Urinary Incontinence
2.3.2 Diagnosis and Treatments
2.3.2.1 Surgery & Devices for Urinary Incontinence
2.3.2.1.1 Slings
2.3.2.1.2 Artificial Urinary Sphincter for Men
2.3.2.1.3 Sacral Nerve Stimulation
2.3.2.1.4 Urethral Bulking Agents (Injectables)
2.3.2.1.5 Other Devices
2.4 Prostate Cancer
2.4.1 Diagnosis and Treatments
2.4.1.1 Radical Retropubic Prostatectomy
2.4.1.2 Prostate Brachytherapy
2.4.1.3 External Beam Radiation
2.4.1.4 Cryosurgery for Prostate Cancer
2.4.1.5 High-intensity Focused Ultrasound (HIFU)
2.5 Regulation of Medical Devices
2.5.1 The US Approval and Regulation System
2.5.2 The EU Approval and Regulation System
2.5.2.1 Post Marketing Surveillance in the EU
3. THE GLOBAL UROLOGY DEVICES MARKET, 2011-2022
3.1 The Global Medical Devices Market, 2011
3.2 The Global Urology Devices Market, 2011
3.2.1 Global Urology Devices Market Forecast, 2012-2016
3.2.2 Global Urology Devices Market Forecast, 2016-2022
4. THE URINARY INCONTINENCE DEVICES MARKET, 2011-2022
4.1 The Urinary Incontinence Devices Market, 2011
4.2 Urinary Incontinence Devices Market Forecast, 2012-2022
4.2.1 Intensely Competitive Market
4.2.2 Decline in Social Stigma is Resulting in Earlier Diagnosis
4.2.3 Changes to Reimbursement in the US has Benefited the UI Market in Recent Years
4.2.4 Changes to Regulations in the US May Slow Growth
4.2.5 Leading Providers of Technologically Advanced UI Devices
4.3 Promising UI Treatments in the Pipeline
4.3.1 EMKinetics
4.3.1.1 EMK TranStim Clinical Research Study
4.3.2 Ferti Care: Transcutaneous Mechanical Nerve Stimulation (TMNS) in the Treatment of Incontinence
5. THE BENIGN PROSTATIC HYPERPLASIA DEVICES MARKET, 2011-2022
5.1 The Benign Prostatic Hyperplasia Devices Market, 2011
5.2 Benign Prostatic Hyperplasia Devices Market Forecast, 2012-2022
5.2.1 Increasing Prevalence of BPH will Keep the Market Expanding
5.2.2 Low Patient Compliance to Medications Ensures Strong Demand for Devices
5.2.3 Demographics and Continued Innovation will Offset Economic Issues in the Market
5.3 Promising BPH Devices in the Pipeline
5.3.1 NeoTract Inc.
5.3.1.1 UroLift System Clinical Trials
6. THE PROSTATE CANCER DEVICES MARKET, 2011-2022
6.1 The Prostate Cancer Devices Market, 2011
6.2 The Prostate Cancer Devices Market Forecast, 2012-2022
6.2.1 Increasing Procedure Volume will Continue Expanding the Market
6.2.2 Brachytherapy Market will Grow Significantly in the Coming Years
6.2.3 Robotic Prostatectmoy will Boost Growth Over the Forecast Period
6.3 Promising Prostate Cancer Treatment Devices in the Pipeline
6.3.1 Augmenix Inc.
6.3.1.1 SpaceOAR System Pivotal Study
7. THE KIDNEY STONE DEVICES MARKET, 2011-2012
7.1 The Kidney Stones Devices Market, 2011
7.2 The Kidney Stone Devices Market Forecast, 2012-2022
7.2.1 An Aging Population and Increasing Prevalence of Kidney Stone Disease will Drive the Market in Coming Years
7.2.2 ISWL Technologies will be the Main Drivers of Growth Over the Forecast Period
8. LEADING NATIONAL UROLOGY DEVICES MARKET, 2012-2022
8.1 Regional Breakdown of the Global Urology Devices Market, 2011
8.2 The Global Urology Devices Market: Regional Forecast, 2012-2022
8.3 The US Urology Devices Market
8.3.1 Prostate Cancer Devices will Boost Growth in the US Market
8.3.2 Positive Reimbursement Landscape in the UI market
8.3.3 Safety Concerns Regarding Female Mesh Slings Could Affect the Market
8.3.4 Potential Effects of Upcoming Medical Device Excise Tax
8.4 The European Urology Device Market
8.4.1 Leading Companies in Europe
8.4.2 France and Germany
8.4.3 UK
8.4.4 Spain
8.4.5 Italy
8.5 The Japanese Urology Devices Market
8.6 The Chinese Urology Devices Market
8.6.1 Chinese Aging Population will Increase Demand Over the Next Decade
8.6.2 Increasing Affluence in China will Boost Demand for High-End Technologies
8.7 The Indian Urology Devices Market
9. LEADING COMPANIES IN THE UROLOGY DEVICES MARKET, 2011
9.1 Intensively Competitive Market
9.2 Leading Companies in the Urology Devices Market, 2011
9.3 C.R. Bard
9.3.1 Recent Performance and Analysis, 2011
9.3.2 Recent M&A Activity
9.3.3 Urology Devices
9.3.4 C.R. Bard: Key Urology Devices, 2011
9.4 Coloplast
9.4.1 Recent Performance and Analysis, 2011
9.4.2 Recent M&A Activity, 2011
9.4.3 Urology Devices
9.4.3.1 Coloplast Maintains Competitive Position in the Global Urology Devices Market in 2011
9.4.3.2 Coloplast Remains the Global Leader in the Continence Care Market
9.4.3.3 Urology Patent Disputes
9.4.3.4 Coloplast: Key Urology Devices, 2011
9.5 Endo Pharmaceuticals Holding, Inc.
9.5.1 Recent Performance and Analysis, 2011
9.5.2 Research and Development Efforts, 2011
9.5.3 Recent M&A Activity
9.5.4 Urology Devices
9.5.4.1 Endo Pharmaceuticals: Key Urology Devices, 2011
9.6 Olympus Corporation
9.6.1 Sales and Recent Peformance Analysis, 2011
9.6.2 Recent Acquisitions
9.6.3 Olympus Medical Business: Urology Devices
9.6.3.1 Key Urology Devices, 2011
9.7 Teleflex Inc.
9.7.1 Sales and Recent Performance Analysis, 2011
9.7.2 Teleflex: Urology Devices
9.7.2.1 Changes in Reimbursement in the US Benefit Teleflex Sales
9.7.2.2 Teleflex: Key Urology Devices, 2011
9.7.3 Recent M&A Activity
9.8 Karl Storz
9.8.1Urology Devices
9.9 Companies with Cost-effective Products will Experience Significant Growth
9.10 Other Companies
10. SWOT ANALYSIS OF THE UROLOGY DEVICES MARKET, 2012
10.1 Urology Devices: Industry Trends
10.2 Strengths
10.2.1 A Global Aging Population
10.2.2 Escalating Levels of Worldwide Obesity Amongst the Population
10.2.3 Strong R&D Pipeline Focused on Cost-Effectiveness
10.2.4 Increasing Demand for Minimally Invasive Procedures
10.3 Weaknesses
10.3.1 Poor Economic Conditions in Key Regional Markets
10.3.2 Social Stigma Associated with Urologic Conditions
10.3.3 Safety Concerns in the UI Market
10.4 Opportunities
10.4.1 Increasing Wealth and Expanding Healthcare Coverage in Emerging Markets
10.4.2 Increasing Regulatory Harmonisation Across Major International Markets
10.5 Threats
10.5.1 Comparative Effectiveness Research as an Added Expense
10.5.2 Increasing Bargaining Power of Buyers
10.5.3 Increasing Competition from Pharmacological Options
11. EXPERT OPINION
11.1 Dr. Idan Tamir, CEO, Xenolith Medical
11.1.1 The Urological Device Market
11.1.2 The Impact of Current Regulations in the European and US Medical Devices Market
11.1.3 Current Challenges for Development-Stage Medical Device Companies
11.1.4 XenX: Commercialisation Plan
11.1.5 XenX: Key Adavantages Over Competitors in the Market
11.1.6 The Importance of Expanding into the Emerging Markets
11.1.7 Future projections for the Endourological Device Market
12. CONCLUSIONS
12.1 Overview
12.2 Urinary Incontinence Devices will Remain the Largest Segment
12.3 Prominent Companies in the Market
12.4 The US will Remain the Largest Market for Urology Devices
12.5 Future Outlook and Concluding Remarks
Appendix A
About Visiongain
Appendix B
Visiongain report evaluation form
LIST OF TABLES
Table 2.1 Classification, Description and Prevalence of Kidney Stones
Table 3.1 The Medical Device Market: Global Revenues ($bn) and Market Shares (%) by Sector, 2011
Table 3.2 Urology Devices Market: Global Revenues ($bn) and Market Shares (%) by Segment, 2011
Table 3.3 The Global Urology Devices Market Forecast ($bn), 2011-2016
Table 3.4 The Global Urology Devices Market Forecast ($bn), 2016-2022
Table 3.5 Global Urology Devices Market: Drivers and Restraints, 2012-2022
Table 4.1 Urinary Incontinence Market: Revenues ($bn) and Market Shares (%) by Sector, 2011
Table 4.2 The Urinary Incontinence Devices Market Forecast ($bn), 2011-2022
Table 5.1 The BPH Devices Market: Revenues ($bn) and Market Shares (%) by Sector, 2011
Table 5.2 The BPH Devices Market Forecast ($bn), 2011-2022
Table 6.1 The Prostate Cancer Devices Market: Revenues ($m) and Market Shares (%) by Sector, 2011
Table 6.2 The Prostate Cancer Devices Market Forecast ($bn), 2011-2022
Table 7.1 Kidney Stones Devices Market: Revenues ($m) and Market Shares (%) by Sector, 2011
Table 7.2 The Kidney Stone Devices Market Forecast ($bn), 2011-2022
Table 8.1 Urology Devices Market: Regional Sales ($bn) and Market Shares (%), 2011
Table 8.2 Global Urology Devices Market: Regional Revenues ($bn), 2011-2016
Table 8.3 Global Urology Devices Market: Regional Revenues ($bn), 2016-2022
Table 8.4 The US Urology Devices Market Forecast Summary: Size ($bn), Rank, Share (%), CAGR (%), 2011-2022
Table 8.5 The European Urology Devices Market Forecast Summary: Size ($bn), Rank, Share (%), CAGR (%), 2011-2022
Table 8.6 The Leading European Urology Devices National Market by Revenue ($bn), 2011
Table 8.7 The European Urology Devices Market Forecast: Revenues ($bn) by Country, 2011-2016
Table 8.8 The European Urology Devices Market Forecast: Revenues ($bn) by Country, 2016-2022
Table 8.9 The Japanese Urology Devices Market Forecast Summary: Size ($bn), Rank, Share (%), CAGR (%), 2011-2022
Table 8.10 The Chinese Urology Devices Market Forecast Summary: Size ($bn), Rank, Share (%), CAGR (%), 2011-2022
Table 8.11 The Indian Urology Devices Market Forecast Summary: Size ($bn), Rank, Share (%), CAGR (%), 2011-2022
Table 9.1 Leading Companies in the Urology Devices Market: Total Sales ($bn), 2011
Table 9.2 C.R. Bard: Revenues ($bn) and Market Shares (%) by Business Segments, 2011
Table 9.3 C.R. Bard: Revenues ($bn) and Market Shares (%) by Region, 2011
Table 9.4 C.R. Bard: Recent M&A Activity, Transaction value ($m) and Date of Transaction.
Table 9.5 C.R. Bard: Percentage Change (%) in Net Sales of Urological Products, 2011
Table 9.6 C.R. Bard: Key Selected Urology Devices, 2011
Table 9.7 Coloplast: Revenues ($bn) and Market Shares (%) by Business Segments, 2011
Table 9.8 Coloplast: Revenues ($bn) and Market Shares (%) by Region, 2011
Table 9.9 Coloplast: Key Selected Urology Devices, 2011
Table 9.10 Endo Pharmaceuticals: Revenues ($bn) and Market Shares (%) by Business Segments, 2011
Table 9.11 Endo Pharmaceuticals: R&D Expense ($m) by Segment, 2011
Table 9.12 Endo Pharmaceuticals: Recent M&A Activity, Transaction ($bn), Date of Transaction and Market
Table 9.13 Endo Pharmaceuticals Devices: Revenue ($bn) and Market Shares (%) by Region, 2011
Table 9.14 Endo Pharmaceuticals: Key Selected Urology Devices, 2011
Table 9.15 Olympus: Revenues ($bn) and Market Shares (%) by Business Segments, 2011
Table 9.16 Olympus: Revenues ($bn) and Market Share (%) by Region, 2011
Table 9.17 Olympus Medical Business: Revenues ($bn) and Market Shares (%) by Product Line, 2011
Table 9.18 Olympus Medical Business: Revenues ($bn) and Market Shares (%) by Region, 2011
Table 9.19 Olympus: Key Selected Urology Devices, 2011
Table 9.20 Teleflex: Revenues ($m) and Market Shares (%) by Business Segments, 2011
Table 9.21 Teleflex: Revenue ($m) and Market Shares (%) by Region, 2011
Table 9.22 Teleflex: Selected List of Key Urology Devices, 2011
Table 9.23 Selected List of Other Companies Operating in the Urology Devices Market, 2012
Table 10.1 SWOT Analysis of the Urology Devices Market, 2012
Table 12.1 Projected Total Urology Devices Market Size ($bn) in 2011, 2016, 2018, and 2022
Table 2.1 Classification, Description and Prevalence of Kidney Stones
Table 3.1 The Medical Device Market: Global Revenues ($bn) and Market Shares (%) by Sector, 2011
Table 3.2 Urology Devices Market: Global Revenues ($bn) and Market Shares (%) by Segment, 2011
Table 3.3 The Global Urology Devices Market Forecast ($bn), 2011-2016
Table 3.4 The Global Urology Devices Market Forecast ($bn), 2016-2022
Table 3.5 Global Urology Devices Market: Drivers and Restraints, 2012-2022
Table 4.1 Urinary Incontinence Market: Revenues ($bn) and Market Shares (%) by Sector, 2011
Table 4.2 The Urinary Incontinence Devices Market Forecast ($bn), 2011-2022
Table 5.1 The BPH Devices Market: Revenues ($bn) and Market Shares (%) by Sector, 2011
Table 5.2 The BPH Devices Market Forecast ($bn), 2011-2022
Table 6.1 The Prostate Cancer Devices Market: Revenues ($m) and Market Shares (%) by Sector, 2011
Table 6.2 The Prostate Cancer Devices Market Forecast ($bn), 2011-2022
Table 7.1 Kidney Stones Devices Market: Revenues ($m) and Market Shares (%) by Sector, 2011
Table 7.2 The Kidney Stone Devices Market Forecast ($bn), 2011-2022
Table 8.1 Urology Devices Market: Regional Sales ($bn) and Market Shares (%), 2011
Table 8.2 Global Urology Devices Market: Regional Revenues ($bn), 2011-2016
Table 8.3 Global Urology Devices Market: Regional Revenues ($bn), 2016-2022
Table 8.4 The US Urology Devices Market Forecast Summary: Size ($bn), Rank, Share (%), CAGR (%), 2011-2022
Table 8.5 The European Urology Devices Market Forecast Summary: Size ($bn), Rank, Share (%), CAGR (%), 2011-2022
Table 8.6 The Leading European Urology Devices National Market by Revenue ($bn), 2011
Table 8.7 The European Urology Devices Market Forecast: Revenues ($bn) by Country, 2011-2016
Table 8.8 The European Urology Devices Market Forecast: Revenues ($bn) by Country, 2016-2022
Table 8.9 The Japanese Urology Devices Market Forecast Summary: Size ($bn), Rank, Share (%), CAGR (%), 2011-2022
Table 8.10 The Chinese Urology Devices Market Forecast Summary: Size ($bn), Rank, Share (%), CAGR (%), 2011-2022
Table 8.11 The Indian Urology Devices Market Forecast Summary: Size ($bn), Rank, Share (%), CAGR (%), 2011-2022
Table 9.1 Leading Companies in the Urology Devices Market: Total Sales ($bn), 2011
Table 9.2 C.R. Bard: Revenues ($bn) and Market Shares (%) by Business Segments, 2011
Table 9.3 C.R. Bard: Revenues ($bn) and Market Shares (%) by Region, 2011
Table 9.4 C.R. Bard: Recent M&A Activity, Transaction value ($m) and Date of Transaction.
Table 9.5 C.R. Bard: Percentage Change (%) in Net Sales of Urological Products, 2011
Table 9.6 C.R. Bard: Key Selected Urology Devices, 2011
Table 9.7 Coloplast: Revenues ($bn) and Market Shares (%) by Business Segments, 2011
Table 9.8 Coloplast: Revenues ($bn) and Market Shares (%) by Region, 2011
Table 9.9 Coloplast: Key Selected Urology Devices, 2011
Table 9.10 Endo Pharmaceuticals: Revenues ($bn) and Market Shares (%) by Business Segments, 2011
Table 9.11 Endo Pharmaceuticals: R&D Expense ($m) by Segment, 2011
Table 9.12 Endo Pharmaceuticals: Recent M&A Activity, Transaction ($bn), Date of Transaction and Market
Table 9.13 Endo Pharmaceuticals Devices: Revenue ($bn) and Market Shares (%) by Region, 2011
Table 9.14 Endo Pharmaceuticals: Key Selected Urology Devices, 2011
Table 9.15 Olympus: Revenues ($bn) and Market Shares (%) by Business Segments, 2011
Table 9.16 Olympus: Revenues ($bn) and Market Share (%) by Region, 2011
Table 9.17 Olympus Medical Business: Revenues ($bn) and Market Shares (%) by Product Line, 2011
Table 9.18 Olympus Medical Business: Revenues ($bn) and Market Shares (%) by Region, 2011
Table 9.19 Olympus: Key Selected Urology Devices, 2011
Table 9.20 Teleflex: Revenues ($m) and Market Shares (%) by Business Segments, 2011
Table 9.21 Teleflex: Revenue ($m) and Market Shares (%) by Region, 2011
Table 9.22 Teleflex: Selected List of Key Urology Devices, 2011
Table 9.23 Selected List of Other Companies Operating in the Urology Devices Market, 2012
Table 10.1 SWOT Analysis of the Urology Devices Market, 2012
Table 12.1 Projected Total Urology Devices Market Size ($bn) in 2011, 2016, 2018, and 2022
LIST OF FIGURES
Figure 3.1 Revenues ($bn) of Leading Sectors in the Medical Device Market, 2011
Figure 3.2 The Medical Device Market: Global Market Shares (%) by Sector, 2011
Figure 3.3 Urology Devices Market: Global Revenues ($bn) by Segment, 2011
Figure 3.4 Global Urology Devices Market: Market Shares (%) by Segment, 2011
Figure 3.5 The Global Urology Devices Market Forecast ($bn), 2011-2016
Figure 3.6 The Global Urology Devices Market Forecast ($bn), 2016-2022
Figure 4.1 Urinary Incontinence Market: Revenues ($bn) by Sector, 2011
Figure 4.2 Urinary Incontinence Market: Market Shares (%) by Sector, 2011
Figure 4.3 The Urinary Incontinence Market Forecast ($bn), 2011-2012
Figure 5.1 The BPH Devices Market: Revenues ($bn) by Sector, 2011
Figure 5.2 The BPH Devices Market: Market Shares (%) by Sector, 2011
Figure 5.3 The BPH Devices Market Forecast ($bn), 2011-2022
Figure 6.1 The Prostate Cancer Devices Market: Revenues ($m) by Sector, 2011
Figure 6.2 The Prostate Cancer Devices Market: Market Shares (%) by Sector, 2011
Figure 6.3 The Prostate Cancer Devices Market Forecast ($bn), 2011-2022
Figure 7.1 Kidney Stone Devices Market: Revenues ($m) by Sector, 2011
Figure 7.2 Kidney Stone Devices Market: Market Shares (%) by Sector, 2011
Figure 7.3 The Kidney Stone Devices Market Forecast ($bn), 2011-2022
Figure 8.1 Urology Devices Market: Regional Sales ($bn), 2011
Figure 8.2 Urology Devices Market: Regional Market Shares (%), 2011
Figure 8.3 Regional Urology Devices Market Forecast: CAGR (%), 2011-2016
Figure 8.4 Regional Urology Devices Market Forecast: CAGR (%), 2016-2022
Figure 8.5 Regional Urology Devices Market Forecast: CAGR (%), 2011-2022
Figure 8.6 The US Urology Devices Market: Revenues ($bn), 2011-2022
Figure 8.7 US Demographics: No. of People Aged 65 or Over, 2012 & 2022
Figure 8.8 The European Urology Devices Market: Revenues ($bn) by Leading Countries, 2011
Figure 8.9 The European Urology Devices Market: Market Shares (%) by Leading Countries, 2011
Figure 8.10 European Urology Devices Market Forecast: CAGR (%), 2011-2022
Figure 8.11 European Urology Devices Market Forecast: Revenues ($bn), 2011-2022
Figure 8.12 The German and French Urology Devices Market Forecast: Revenues ($bn), 2011-2022
Figure 8.13 The UK Urology Devices Market Forecast: Revenues ($bn), 2011-2022
Figure 8.14 The Spanish Urology Devices Market Forecast: Revenues ($bn), 2011-2022
Figure 8.15 The Italian Urology Devices Market Forecast: Revenues ($bn), 2011-2022
Figure 8.16 The Japanese Urology Devices Market Forecast: Revenues ($bn), 2011-2022
Figure 8.17 The Chinese Urology Devices Market Forecast: Revenues ($bn), 2011-2022
Figure 8.18 Chinese Population Aged 65 or over: 1950-2050
Figure 8.19 The Indian Urology Devices Market Forecast: Revenues ($bn), 2011-2022
Figure 9.1 Leading Companies in the Urology Devices Market: Net Sales ($bn), 2011
Figure 9.2 C.R. Bard: Revenues ($bn) by Business Segments, 2011
Figure 9.3 C.R. Bard: Market Shares (%) by Business Segments, 2011
Figure 9.4 C.R. Bard: Percentage Change (%) in Net Sales by Sector, Fiscal Year 2009-2010 & 2010-2011
Figure 9.5 C.R. Bard: Market Shares (%) by Region, 2011
Figure 9.6 C.R. Bard: Percentage Change (%) in Net Sales of Urology Products, 2011
Figure 9.7 Coloplast: Revenues ($bn) by Business Segments, 2011
Figure 9.8 Coloplast: Market Shares (%) by Business Segments, 2011
Figure 9.9 Coloplast: Revenues ($bn) by Region, 2011
Figure 9.10 Coloplast: Market Shares (%) by Region, 2011
Figure 9.11 Endo Pharmaceuticals: Revenues ($bn) by Business Segments, 2011
Figure 9.12 Endo Pharmaceuticals: Market Shares (%) by Business Segments, 2011
Figure 9.13 Endo Pharmaceuticals: R&D Expenditure by Segment, 2011
Figure 9.14 Endo Pharmaceuticals Devices: Market Shares (%) by Region, 2011
Figure 9.15 Olympus: Revenues ($bn) by Business Segments, 2011
Figure 9.16 Olympus: Market Shares (%) by Business Segments, 2011
Figure 9.17 Olympus: Market Shares (%) by Region, 2011
Figure 9.18 Olympus Medical Business: Market Shares (%) by Product Line, 2011
Figure 9.19 Olympus Medical Business: Revenues ($bn) by Region, 2011
Figure 9.20 Olympus Medical Business: Market Shares (%) by Region, 2011
Figure 9.21 Teleflex: Revenues ($m) by Business Segments, 2011
Figure 9.22 Teleflex: Market Shares (%) by Business Segments, 2011
Figure 9.23 Teleflex: Revenue ($m) by Region, 2011
Figure 9.24 Teleflex: Market Shares (%) by Region, 2011
Figure 10.1 Proportion of Population Aged 60 or Over: World, 1950-2050
Figure 12.1 Projected Total Urology Devices Market Size ($bn) in 2011, 2016, 2018, and 2022
Figure 12.2 Projected Market Size ($bn): Urinary Incontinence Devices, Prostate Cancer Devices, BPH Devices and Kidney Stones Devices in 2011, 2016, 2018 and 2022
COMPANIES LISTED
Allengers Medical Systems
Allergan
American Medical Systems
Asahi Kasei Corporation
AstraTec
Augmenix Inc (US)
B.Braun Melsungen AG
Baxter International
Boston Scientific
C.R. Bard
Caldera Medical
Coloplast
Cook Medical
Covidien
DirexGroup
Dornier MedTech GmbH
EDAP TMS SA
Electro Medical Systems
EMK Kinetics
Endo Health Solutions
Endopharmaceutical Holdings
Ethicon
First Quality Enterprises
Fresenius Medical Care
Gen-Probe (US)
GlaxoSmithKline
Gyne Ideas
Healthtronics
Hollister
Hologic Incorporated
Hunter Urology (UK)
Intuitive Surgical
Johnson & Johnson
Karl Storz
Kimberly-Clark Corporation
Kobayashi Pharmaceutical
Laborie
Medical Service (Germany)
Medline Industries
Medtronic
Mpathy Medical Devices
Multicept (Denmark)
NeoTract (US)
Nihon Kohden
NIPRO CORPORATION
Novartis
Olympus Medical Systems Corp
Ontex International
Pfizer
ProUroCare
Richard Wolf GmbH
Storz Medical AG
Svenska Cellulosa Aktiebolaget SCA
TARIS Biomedical
Teleflex Incorporated
TENA
Uromed
Uroplasty
Varian Medical Systems
Xenolith Medical
Zynex
GOVERNMENT AGENCIES AND OTHER ORGANISATIONS MENTIONED IN THIS REPORT
FDA
EMA
GHTF
IMDRF
UN
WHO
EUDAMED
CDRH
China's Ministry of Science and Technology
Figure 3.1 Revenues ($bn) of Leading Sectors in the Medical Device Market, 2011
Figure 3.2 The Medical Device Market: Global Market Shares (%) by Sector, 2011
Figure 3.3 Urology Devices Market: Global Revenues ($bn) by Segment, 2011
Figure 3.4 Global Urology Devices Market: Market Shares (%) by Segment, 2011
Figure 3.5 The Global Urology Devices Market Forecast ($bn), 2011-2016
Figure 3.6 The Global Urology Devices Market Forecast ($bn), 2016-2022
Figure 4.1 Urinary Incontinence Market: Revenues ($bn) by Sector, 2011
Figure 4.2 Urinary Incontinence Market: Market Shares (%) by Sector, 2011
Figure 4.3 The Urinary Incontinence Market Forecast ($bn), 2011-2012
Figure 5.1 The BPH Devices Market: Revenues ($bn) by Sector, 2011
Figure 5.2 The BPH Devices Market: Market Shares (%) by Sector, 2011
Figure 5.3 The BPH Devices Market Forecast ($bn), 2011-2022
Figure 6.1 The Prostate Cancer Devices Market: Revenues ($m) by Sector, 2011
Figure 6.2 The Prostate Cancer Devices Market: Market Shares (%) by Sector, 2011
Figure 6.3 The Prostate Cancer Devices Market Forecast ($bn), 2011-2022
Figure 7.1 Kidney Stone Devices Market: Revenues ($m) by Sector, 2011
Figure 7.2 Kidney Stone Devices Market: Market Shares (%) by Sector, 2011
Figure 7.3 The Kidney Stone Devices Market Forecast ($bn), 2011-2022
Figure 8.1 Urology Devices Market: Regional Sales ($bn), 2011
Figure 8.2 Urology Devices Market: Regional Market Shares (%), 2011
Figure 8.3 Regional Urology Devices Market Forecast: CAGR (%), 2011-2016
Figure 8.4 Regional Urology Devices Market Forecast: CAGR (%), 2016-2022
Figure 8.5 Regional Urology Devices Market Forecast: CAGR (%), 2011-2022
Figure 8.6 The US Urology Devices Market: Revenues ($bn), 2011-2022
Figure 8.7 US Demographics: No. of People Aged 65 or Over, 2012 & 2022
Figure 8.8 The European Urology Devices Market: Revenues ($bn) by Leading Countries, 2011
Figure 8.9 The European Urology Devices Market: Market Shares (%) by Leading Countries, 2011
Figure 8.10 European Urology Devices Market Forecast: CAGR (%), 2011-2022
Figure 8.11 European Urology Devices Market Forecast: Revenues ($bn), 2011-2022
Figure 8.12 The German and French Urology Devices Market Forecast: Revenues ($bn), 2011-2022
Figure 8.13 The UK Urology Devices Market Forecast: Revenues ($bn), 2011-2022
Figure 8.14 The Spanish Urology Devices Market Forecast: Revenues ($bn), 2011-2022
Figure 8.15 The Italian Urology Devices Market Forecast: Revenues ($bn), 2011-2022
Figure 8.16 The Japanese Urology Devices Market Forecast: Revenues ($bn), 2011-2022
Figure 8.17 The Chinese Urology Devices Market Forecast: Revenues ($bn), 2011-2022
Figure 8.18 Chinese Population Aged 65 or over: 1950-2050
Figure 8.19 The Indian Urology Devices Market Forecast: Revenues ($bn), 2011-2022
Figure 9.1 Leading Companies in the Urology Devices Market: Net Sales ($bn), 2011
Figure 9.2 C.R. Bard: Revenues ($bn) by Business Segments, 2011
Figure 9.3 C.R. Bard: Market Shares (%) by Business Segments, 2011
Figure 9.4 C.R. Bard: Percentage Change (%) in Net Sales by Sector, Fiscal Year 2009-2010 & 2010-2011
Figure 9.5 C.R. Bard: Market Shares (%) by Region, 2011
Figure 9.6 C.R. Bard: Percentage Change (%) in Net Sales of Urology Products, 2011
Figure 9.7 Coloplast: Revenues ($bn) by Business Segments, 2011
Figure 9.8 Coloplast: Market Shares (%) by Business Segments, 2011
Figure 9.9 Coloplast: Revenues ($bn) by Region, 2011
Figure 9.10 Coloplast: Market Shares (%) by Region, 2011
Figure 9.11 Endo Pharmaceuticals: Revenues ($bn) by Business Segments, 2011
Figure 9.12 Endo Pharmaceuticals: Market Shares (%) by Business Segments, 2011
Figure 9.13 Endo Pharmaceuticals: R&D Expenditure by Segment, 2011
Figure 9.14 Endo Pharmaceuticals Devices: Market Shares (%) by Region, 2011
Figure 9.15 Olympus: Revenues ($bn) by Business Segments, 2011
Figure 9.16 Olympus: Market Shares (%) by Business Segments, 2011
Figure 9.17 Olympus: Market Shares (%) by Region, 2011
Figure 9.18 Olympus Medical Business: Market Shares (%) by Product Line, 2011
Figure 9.19 Olympus Medical Business: Revenues ($bn) by Region, 2011
Figure 9.20 Olympus Medical Business: Market Shares (%) by Region, 2011
Figure 9.21 Teleflex: Revenues ($m) by Business Segments, 2011
Figure 9.22 Teleflex: Market Shares (%) by Business Segments, 2011
Figure 9.23 Teleflex: Revenue ($m) by Region, 2011
Figure 9.24 Teleflex: Market Shares (%) by Region, 2011
Figure 10.1 Proportion of Population Aged 60 or Over: World, 1950-2050
Figure 12.1 Projected Total Urology Devices Market Size ($bn) in 2011, 2016, 2018, and 2022
Figure 12.2 Projected Market Size ($bn): Urinary Incontinence Devices, Prostate Cancer Devices, BPH Devices and Kidney Stones Devices in 2011, 2016, 2018 and 2022
COMPANIES LISTED
Allengers Medical Systems
Allergan
American Medical Systems
Asahi Kasei Corporation
AstraTec
Augmenix Inc (US)
B.Braun Melsungen AG
Baxter International
Boston Scientific
C.R. Bard
Caldera Medical
Coloplast
Cook Medical
Covidien
DirexGroup
Dornier MedTech GmbH
EDAP TMS SA
Electro Medical Systems
EMK Kinetics
Endo Health Solutions
Endopharmaceutical Holdings
Ethicon
First Quality Enterprises
Fresenius Medical Care
Gen-Probe (US)
GlaxoSmithKline
Gyne Ideas
Healthtronics
Hollister
Hologic Incorporated
Hunter Urology (UK)
Intuitive Surgical
Johnson & Johnson
Karl Storz
Kimberly-Clark Corporation
Kobayashi Pharmaceutical
Laborie
Medical Service (Germany)
Medline Industries
Medtronic
Mpathy Medical Devices
Multicept (Denmark)
NeoTract (US)
Nihon Kohden
NIPRO CORPORATION
Novartis
Olympus Medical Systems Corp
Ontex International
Pfizer
ProUroCare
Richard Wolf GmbH
Storz Medical AG
Svenska Cellulosa Aktiebolaget SCA
TARIS Biomedical
Teleflex Incorporated
TENA
Uromed
Uroplasty
Varian Medical Systems
Xenolith Medical
Zynex
GOVERNMENT AGENCIES AND OTHER ORGANISATIONS MENTIONED IN THIS REPORT
FDA
EMA
GHTF
IMDRF
UN
WHO
EUDAMED
CDRH
China's Ministry of Science and Technology
